

- **Name:** David S. Hong
- **Current Position & Affiliation:** Professor and Deputy Chair, Dept of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- **Country:** USA

• **Educational Background:**

Institution	Degree	Year	Field of Study
Yale University, New Haven	BS	1993	Oncology
Albert Einstein College of Medicine, New York	MD	1999	Medicine
Thomas Jefferson University Hospital, Philadelphia	Clinical Residency	6/1999-1/2001	Internal Medicine
The University of Texas MD Anderson Cancer Center, Houston	Clinical Fellowship	6/2002-6/2005	Medical Oncology
NCI-CTEP, Bethesda	Rotation	9/2004-10/2004	

• **Professional Experience:**

- 2021-present Clinical Medical Director, Clinical and Translational Research Center, The University of Texas MD Anderson Cancer Center
- 2017-present Professor, Department of Investigational Cancer Therapeutics Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- 2017-present Associate Vice President of Clinical Research The University of Texas MD Anderson Cancer Center
- 2013-present Deputy Chair, Department of Investigational Cancer Therapeutics Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- 2012-2017 Associate Professor, Department of Investigational Cancer Therapeutics Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- 2007-2012 Assistant Professor, Department of Investigational Cancer Therapeutics Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
- 2007-2018 Clinical Medical Director, Clinical Center for Targeted Therapy The University of Texas MD Anderson Cancer Center, Houston
- 2005-2007 Assistant Professor, Department of Gastrointestinal Medical Oncology Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

• **Professional Organizations:**

- 2018-present Member, PEP-CTN Agent Prioritization Committee, National Cancer Institute
- 2018-present Clinical Trials Advisory Committee, Cancer Prevention and Research Institute of Texas
- 2018-present Lead, Adaptimmune Alliance, Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center

15<sup>th</sup> Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

2014-2018	Lead, Bayer/MDACC Alliance, Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center
2012-2016	Director, Investigational Cancer Therapeutics Fellowship Program The University of Texas MD Anderson Cancer Center
2009-2012	Associate Scientific Editor, Science Translational Medicine
2009-2010	Quality Officer, Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center
2005-2009	Editor, Current Oncology Reports
2005-present	Member, CRC 4 Committee, The University of Texas MD Anderson Cancer Center
2004-2005	Chief Medical Oncology Fellow, The University of Texas MD Anderson Cancer Center

**• Main Scientific Publications:**

1. **Hong DS**, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou A, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF V600E mutation. *Cancer Discov* 6(12):1352-1365, 12/2016. e-Pub 10/2016. PMID: 27729313
2. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M1, Rudzinski ER1, Meric-Bernstam F1, Sohal DPS1, Ma PC1, Raez LE1, Hechtman JF1, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, **Hong DS**, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *New Engl J Med* 378(8):731-739, 2/2018. PMID: 29466156
3. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakhri MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, **Hong DS**, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 575(7781):217-223, 11/2019. e-Pub 10/2019. PMID: 31666701
4. **Hong DS**, Fakhri MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors. *N Engl J Med* 383(13):1207-1217, 9/2020. Epub 9/2020. PMID: 32955176
5. **Hong DS**, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. *Clin Cancer Res* 18(12):3396-406, 6/2012. e-Pub 5/2012. PMID: PMC4494099.